论文部分内容阅读
目的评价TAC方案联合使用绿脓杆菌制剂在乳腺癌新辅助化疗中的价值。方法以随机排列表法将我院2008年1月-2008年6月收治的60例女性乳腺癌患者随机分为实验组(30例)与对照组(30例),两组均采用TAC新辅助化疗方案,实验组加用绿脓杆菌制剂,治疗结束后评价两组的疗效、毒副作用、手术方式、术后并发症及疗效-成本比。结果实验组在新辅助化疗第2、3、4疗程后总有效率(RR)均高于对照组(P<0.05);实验组化疗前后Karnofsky评分无明显差别,而对照组化疗前后Karnofsky评分显著降低(P<0.05);实验组较对照组毒性反应发生率及反应程度明显降低;两组患者手术方式的选择无明显差异;实验组患者出现皮下积液、皮瓣坏死及感染的几率较对照组降低;实验组患者经2次新辅助化疗后即行手术治疗比例较对照组显著增加(P<0.01);第2次新辅助化疗后实验组每增加1%化疗有效率需花费人民币较对照组显著减少(P<0.01)。结论绿脓杆菌制剂在新辅助化疗中的联合使用能增加化疗的疗效,同时能增加患者的化疗承受能力,减轻化疗的毒副作用,而且能减少患者术后并发症的出现,没有加重患者的经济负担,值得临床推广。
Objective To evaluate the value of TAC combined with Pseudomonas aeruginosa in neoadjuvant chemotherapy of breast cancer. Methods Sixty female breast cancer patients who were admitted to our hospital from January 2008 to June 2008 were randomly divided into experimental group (30 cases) and control group (30 cases), all of whom were assisted by TAC Chemotherapy program, experimental group plus Pseudomonas aeruginosa preparation, the treatment after the end of the evaluation of the efficacy of the two groups, side effects, surgical methods, postoperative complications and efficacy - cost ratio. Results The total effective rate (RR) in experimental group after neoadjuvant chemotherapy were higher than those in control group (P <0.05). There was no significant difference in Karnofsky score before and after chemotherapy in the experimental group, but Karnofsky score in the control group before and after chemotherapy (P <0.05). Compared with the control group, the incidence of the toxic reaction and the degree of reaction in the experimental group were significantly decreased. There was no significant difference in the choice of surgical methods between the two groups. The incidence of subcutaneous effusion, flap necrosis and infection in the experimental group was significantly higher than that in the control group (P <0.01). After the second neoadjuvant chemotherapy, every 1% increase in the rate of chemotherapy in the experimental group would cost RMB more than the control group Significantly reduced (P <0.01). Conclusions The combined use of Pseudomonas aeruginosa in neoadjuvant chemotherapy can increase the curative effect of chemotherapy and at the same time increase the patient’s chemotherapy tolerance, reduce the side effects of chemotherapy and reduce the postoperative complications of patients without aggravating the economy of patients Burden, worthy of clinical promotion.